<DOC>
	<DOCNO>NCT00006265</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , gemtuzumab ozogamicin , locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy , cytarabine , use different way stop cancer cell divide stop grow die . Combining gemtuzumab ozogamicin cytarabine may kill cancer cell . PURPOSE : Phase II trial study effectiveness combine gemtuzumab ozogamicin high-dose cytarabine treat patient relapsed refractory acute myeloid leukemia .</brief_summary>
	<brief_title>Gemtuzumab Ozogamicin High-Dose Cytarabine Treating Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient relapse refractory acute myeloid leukemia treat gemtuzumab ozogamicin ( CMA-676 ) high-dose cytarabine . - Determine safety toxicity regimen patient . OUTLINE : This dose-escalation study gemtuzumab ozogamicin ( CMA-676 ) ( phase I close accrual effective 08/25/2003 ) . Patients stratify accord disease status ( refractory v relapse ) . - Phase I ( close accrual effective 08/25/2003 ) : Patients enrol one four cohort . - Cohort I ( close accrual 10/1/02 ) : Patients receive CMA-676 first dose level IV 2 hour day 1 8 . - Cohort IA ( open accrual 10/15/02 ) : Patients receive high-dose cytarabine ( HD-ARA-C ) IV 3 hour day 1-5 CMA-676 IV 2 hour day 7 . - Cohort II : Patients receive HD-ARA-C cohort IA CMA-676 first dose level IV 2 hour day 7 14 . - Cohort IV : Patients receive CMA-676 second dose level HD-ARA-C cohort II . Dose escalation stop least 3 9 patient experience dose-limiting toxicity . - Phase II : Patients receive HD-ARA-C IV 3 hour day 1-5 CMA-676 IV 2 hour day 7 ( one course ) . Patients follow 1 month , monthly 6 month , every 3 month 2 year , annually 10 year . PROJECTED ACCRUAL : A total 36 patient accrued phase I study total 37 patient accrue phase II study within 2 year . ( Phase I close accrual effective 08/25/2003 ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Primary refractory acute myeloid leukemia ( AML ) More 10 % blast bone marrow blood recovery 2 course standard cytarabine anthracyclinebased induction chemotherapy No prior remission Relapsed AML More 10 % blast bone marrow blood document remission Prior remission last 30 day No prior treatment current relapse CD33 expression least 20 % leukemia blast cell initial diagnosis primary refractory patient time relapse patient No active CNS involvement PATIENT CHARACTERISTICS : Age : 17 Performance status : 02 Life expectancy : Not specify Hematopoietic : See Disease Characteristics WBC le 30,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL No venoocclusive disease liver No chronic liver disease unless due AML Renal : Not specify Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active serious infection PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 month since prior stem cell transplantation Chemotherapy : See Disease Characteristics Prior etoposide and/or thioguanine remission induction allow Prior hydroxyurea control AML allow At least 24 hour since prior hydroxyurea At least 3 month since prior highdose cytarabine ( great 2 g/m^2/dose ) contain regimen No concurrent chemotherapy Endocrine therapy : Concurrent steroid adrenal failure , hypersensitivity reaction , septic shock allow Concurrent ophthalmic corticosteroid allow Concurrent hormone nondiseaserelated condition ( e.g. , insulin diabetes estrogens progestin gynecologic condition ) allow Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : More 2 month since prior cytotoxic therapy</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
</DOC>